Los Angeles - (NewMediaWire) - September 28, 2021 - The Schall Law
Firm, a national
shareholder rights litigation firm, reminds investors of a class action lawsuit
against Iterum Therapeutics plc (“Iterum” or “the Company”) (NASDAQ:
ITRM) for
violations of §§10(b)
and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated
thereunder by the U.S. Securities and Exchange Commission.
Investors who
purchased the Company's securities between November 30, 2020 and July 23, 2021,
inclusive (the ''Class Period''), are encouraged to contact the firm before October
4, 2021.
If you are a
shareholder who suffered a loss, click here to participate.
We also encourage you
to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite
2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of
charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this
case, has not yet been certified, and until certification occurs, you are not
represented by an attorney. If you choose to take no action, you can remain an
absent class member.
According to the
Complaint, the Company made false and misleading statements to the market.
Iterum’s New Drug Application (“NDA”) for sulopenem failed to include
sufficient data to support the drug’s approval for the treatment of uncomplicated
urinary tract infections (“uUTIs”) in adult women. It was unlikely the FDA
would approve the Company’s NDA as it was submitted. The Company downplayed the
deficiencies in its NDA. Based on these facts, the Company’s public statements
were false and materially misleading throughout the class period. When the
market learned the truth about Iterum, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm
represents investors around the world and specializes in securities class
action lawsuits and shareholder rights litigation.
This press release may
be considered Attorney Advertising in some jurisdictions under the applicable
law and rules of ethics.
CONTACT:
The Schall
Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
SOURCE:
The Schall Law Firm